跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ILARIS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ILARIS
Authorized
STANDARD
ILARIS
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
7eea2d2df7005108
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
7eea2d2df7005108
Drug Approval Canada Name
ILARIS
Product Name
ILARIS
Status
Marketed
Status Date
2017-08-22
Original Market Date
2017-08-22
Din
02460351
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
90:28.00
Atc Original
L04AC08 CANAKINUMAB
Atc Name
l 04 ac 08
Aig Number
0152696001
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
CANAKINUMAB
150 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
7eea2d2df7005108
Type
Standard
Back to Health Canada Approvals